Article
BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus.
Lupus - 1 Apr 2016
Picceli V F, Skare T L, Nisihara R M, Nass F R, Messias-Reason I T, Utiyama S R R
Abstract excerpt
BACKGROUND: B factor (BF) from the alternative complement pathway seems to participate in the pathophysiology of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). OBJECTIVE: To study the allotypic variability of BF in SLE and their associations with clinical and autoantibodies profile. METHODS: BF allotypes were determined by high-voltage agarose gel electrophoresis, under constant cooling,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.